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Background. Prostate carcinomas are initially dependent on androgens, and castration or androgen antagonists inhibit their
growth. After some time though, tumors become resistant and recur with a poor prognosis. The majority of resistant tumors
still expresses a functional androgen receptor (AR), frequently amplified or mutated. Methodology/Principal Findings. To
test the hypothesis that AR is not only expressed, but is still a key therapeutic target in advanced carcinomas, we injected
siRNA targeting AR into mice bearing exponentially growing castration-resistant tumors. Quantification of siRNA into tumors
and mouse tissues demonstrated their efficient uptake. This uptake silenced AR in the prostate, testes and tumors. AR silencing
in tumors strongly inhibited their growth, and importantly, also markedly repressed the VEGF production and angiogenesis.
Conclusions/Significance. Our results demonstrate that carcinomas resistant to hormonal manipulations still depend on the
expression of the androgen receptor for their development in vivo. The siRNA-directed silencing of AR, which allows targeting
overexpressed as well as mutated isoforms, triggers a strong antitumoral and antiangiogenic effect. siRNA-directed silencing of
this key gene in advanced and resistant prostate tumors opens promising new therapeutic perspectives and tools.
Citation: Compagno D, Merle C, Morin A, Gilbert C, Mathieu JRR, et al (2007) SIRNA-Directed In Vivo Silencing of Androgen Receptor Inhibits the
Growth of Castration-Resistant Prostate Carcinomas. PLoS ONE 2(10): e1006. doi:10.1371/journal.pone.0001006
INTRODUCTION
AR is a ligand-activated transcription factor that plays a pivotal
role in the prostate, regulating a large set of genes involved in cell
division, apoptosis, and angiogenesis. Prostate carcinomas are
initially androgen-dependent (ADCaP) and hormone ablation
efficiently inhibits their growth, although some deleterious side
effects result from the inhibition of AR signaling in normal tissues.
The major limitation of these treatments is the capacity of tumors
to escape and recur [1]. Once tumors became resistant to
castration, the prognosis is poor. Non-specific and toxic che-
motherapies like taxotere are only palliative, and the issue is
usually fatal in less than 2 years. Increasingly, clinical observations
demonstrate that in the majority of castration-resistant prostate
carcinomas (CRCaP, also called hormone-refractory), AR is
expressed and controls transcription. Although hormone ablation
treatments strongly reduce the circulating testosterone levels, the
residual amounts of androgens measured within the tumors of
castration-resistant patients, are sufficient to maintain some AR
signaling [2,3]. Furthermore, several other processes allow CRCaP
bypassing hormonal ablation [4,5]. In experimental tumors,
a moderate overexpression of AR in androgen-dependent tumors
allows experimental tumors bypassing hormone ablation [6]. In
patients, AR overexpression can result from gene amplification,
increased transcription, or stabilization of the AR protein [7],
recently linked to the phosphorylation of some AR residues [8,9].
Other molecular events, such as mutations broadening the ligand
spectrum, or conferring agonist properties to androgen antago-
nists, alterations in nuclear receptor coactivators, ligand-indepen-
dent binding of AR to DNA, were also implicated in AR signaling
in CRCaP [4,5]. The variety of mechanisms that can be selected
by prostate tumor cells to escape androgen-ablation therapies
underlines their plasticity, and suggests that AR expression is
mandatory in CRCaP. However, molecular alterations continue to
accumulate once resistance to hormone ablation is established
[10], and a fraction of aggressive tumors, like the DU145 and PC3
cells, stably silence AR, activate other signaling pathways, and
become truly androgen-independent [11]. Thus, although AR is
functional in most recurrent tumors [5,12], disrupting AR
signaling once the resistant phenotype is established, may not be
sufficient to halt the tumor growth. Studies set up, in cultured cells,
to test this hypothesis lead to contradictory conclusions
[13,14,15,16,17]. Using RNA interference to study in vivo the role
of AR in CRCaP, we demonstrate here that tumors that escaped
hormonal manipulations are still dependent on the androgen
receptor for their in vivo growth: AR silencing in tumors inhibits
cells’ proliferation, induces apoptosis and inhibits angiogenesis.
Moreover, we establish the efficiency, safety and specificity of
synthetic siRNA to treat those advanced tumors.
RESULTS
Silencing of AR in ADCaP
We used in this study RNA interference to investigate in vitro and in
vivo the function of AR in prostate carcinomas. To establish the
technical conditions and specificity of AR silencing, we first used
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Androgens stimulate LNCaP cells’ proliferation whereas castration
and the androgen antagonist bicalutamide inhibit the development
of xenografted LNCaP tumors in mice [18]. We designed and
synthesized two different siRNAs targeting the first exon of AR.
The panAR-siRNA targets a sequence conserved between the
human and mouse AR mRNAs. It silences AR expression in the
mouse Sertoli TM4 as in the human LNCaP cell line (Figure 1A).
In contrast, the hAR-siRNA, which targets the human sequence
but presents 5 mismatches out of 19 with the mouse mRNA,
inhibits AR expression in LNCaP but not in mouse TM4 cells
(Figure 1A). Transfection of AR-siRNA in LNCaP cells strongly
inhibits the androgen-induced transcription of Prostate Specific
Antigen (PSA), a prototypic AR-target gene (Figure 1B).
To set up the technical conditions to silence AR expression in vivo,
we implanted LNCaP cells subcutaneously into male nude mice.
Tumors started to develop after 45 days. Once the measurement of
tumors for 5 days demonstrated their exponential growth (Figure
S1), the mean volume of tumors was 49.768.6 mm
3 (mean6SEM).
Mice were then randomized for treatment and received daily for
2 weeks an intraperitoneal injection (i.p.) of 3 mg( 1 2 5mg.kg
21)o f
unmodified synthetic siRNAs diluted in saline. Half of the mice were
treated with the panAR-siRNA, the other half with a control-siRNA
(cont-siRNA) matching no known mRNA sequences in mouse and
human databanks. The growth of tumors treated with AR-siRNA
wasveryrapidlyarrested,andafter10 days,themeantumorvolume
represented only 15% of the control (Figure 1C). The nuclear AR
labeling observed in cont-siRNA treated tumor cells was no longer
detected in tumors treated with AR-siRNA (Figure 1D, left panel),
where large areas of dead, TUNEL-positive cells were present
(Figure 1D, right panel).
Similarly, the hAR-siRNA also inhibited the LNCaP growth in
vivo, as efficiently as the AR antagonist bicalutamide (Figure 1E).
In this experiment, the mean tumor volume on the first day of
treatment was 109.2630.2 mm
3 (mean6SEM). Half of the
animals in each group were sacrificed on the fourth day of
treatment. At that time, the Prostate Specific Antigen (PSA)
mRNA was strongly repressed in the hAR-siRNA and in the
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Figure 1. Silencing of AR in LNCaP cells and tumors. A: Control (cont)- panAR- or hAR-siRNA were transfected into human LNCaP or into mouse
Sertoli TM4 cells. AR was immunodetected by western blot in cell lysates 2 days after removal of transfection medium. a-tubulin (tub) expression was
used as a loading control. B: Relative PSA mRNA level in LNCaP cells transfected with control or hAR-siRNA and grown for 48 h in the absence of
androgens or in the presence of R1881, 0.5 nM (mean6SE, n=3 independent experiments). Similar results were obtained using the panAR-siRNA.
**p,0.01 as compared to values in the absence of androgens. C: LNCaP cells were subcutaneously injected on day 0 to nude mice. Starting from day
51 (arrow), animals (5 per group) received a daily i.p. injection of 3 mg of cont- (black symbols) or panAR-siRNA (white symbols) diluted in 50 ml saline;
tumor volume (cm
3, mean6SE, n=5). *p,0.05 and **p,0.01 comparing panAR-siRNA to cont-siRNA treated tumors. D: Analysis of AR expression by
immunohistochemistry (left panels) and apoptotic cells by TUNEL (right panels) in representative tumors collected at the end of the experiment
shown in C. E: Mice bearing exponentially growing LNCaP tumors were randomized (12 mice per group) and received daily i.p. injections of cont-
siRNA (black symbols), hAR-siRNA (white symbols) or an oral dose of 50 mg.kg
21 of bicalutamide (grey symbols); tumor volume (cm
3, mean6SE).
*p,0.05 and **p,0.01 comparing hAR-siRNA to cont-siRNA treated tumors. F: On the fourth day of treatment of the experiment shown in E, 6 mice
in each group were sacrificed and AR and PSA mRNA levels were quantified in the tumors by qRT-PCR and normalized with cyclophilin A mRNA level.
Results are expressed relative to the mean level in control tumors. **p,0.01 comparing hAR-siRNA to cont-siRNA treated tumors.
doi:10.1371/journal.pone.0001006.g001
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the hAR-siRNA treated tumors (Figure 1F).
Specificity of the AR-siRNA induced inhibition of
tumor growth
The weight and behavior of mice were not affected by a 3 weeks-
long daily treatment with siRNAs, whatever the sequence used.
After dissection, all organs were carefully examined and appeared
normal with no sign of necrosis. TUNEL labeling did not reveal
apoptosis of any cell type in the liver, including endothelial cells.
Therefore, no toxic effects were observable on a macroscopic level.
Off-targets effects of siRNA, due to their partial complemen-
tarity with mRNA unrelated to the cognate sequence, are almost
impossible to rule out by sequence analysis and siRNA design.
Rescue experiments are inadequate here, because even a modest
increase in AR expression modifies the phenotype of the prostate
tumor cells [6]. Because off-target effects occur independently of
the target [19], we injected AR-siRNA into mice bearing tumors
that do not express AR. We chose the fibrosarcoma JT8 cell line
for this purpose, because we previously demonstrated that
injections of VEGF-siRNA into mice bearing JT8 tumors inhibited
by 70% the VEGF production, resulting in a sustained inhibition
of the tumor growth [20]. In contrast with the VEGF-siRNA, AR-
siRNA did not inhibit the growth of JT8 tumors (Figure S2).
Long dsRNA and viruses activate the interferon/RNAseL
pathway, triggering a non sequence-specific degradation of cellular
RNAs and apoptosis [21]. Naked siRNA, even at a 2.5 mg/kg
regimen, do not activate the interferon pathway [22], but some
authors, using lipid-formulated siRNAs [23], reported such effects,
possibly through the Toll-like receptors, TLR3, TLR7 or TLR8
[23,24]. We therefore quantified the IFN-a protein level in the
serum, and the interferon b mRNA level in the tumors, spleens, or
livers, of mice treated for 3 weeks with panAR-siRNA, hAR-siRNA
orcont-siRNA.NoneofthesiRNAsignificantlymodifiedtheselevels
(Figure S3 and data not shown). In addition, it is noteworthy that
RNAseL/HPC1 is one of the major susceptibility genes identified in
familial prostate cancers [25]. Germline and sporadic mutations of
RNAseL are found in the majority of prostatic tumors, including
LNCaP cells, and result ina reduced enzymatic activity and capacity
of cells to respond to the activation of interferons, likely favoring the
development of prostate tumors [25]. It is therefore highly unlikely
that the inhibition of LNCaP tumor growth observed in AR-siRNA
treated mice results from a non-specific mRNA degradation and
apoptosis induced by interferons.
Silencing of AR in prostate and testes of treated
mice
In patients, castration or AR antagonists affect not only the tumor
cells, but also normal tissues, triggering deleterious side effects.
Development of tumor-selective treatments would reduce these
unwanted effects but could also be less efficient. To address this
question we analyzed the prostate and testes of mice treated for 2
or 3 weeks with daily injections of 3 mg of siRNA. As compared to
cont-siRNA, AR expression was strongly reduced by the pan-AR-
siRNA treatment in epithelial and stromal cells of the ventral
prostate, and in Leydig and Sertoli cells in the testes (Figure 2A).
In the testes, the AR-target gene Glutathione S-transferase alpha
[26] was also inhibited by AR silencing (Figure 2B). As observed
with other AR signaling inhibitors [27], AR silencing in the testes
induced the apoptosis of germ cells (Figure 2C), but not that of the
AR-expressing Leydig and Sertoli cells, further demonstrating the
specificity of the effects triggered by the panAR-siRNA. We
recently reported that AR silencing in the testes inhibits the
Fibroblast Growth Factor-2 synthesis in the germ cells, a mecha-
nism possibly involved in the induction of their apoptosis [28].
Testosterone is mainly produced by the Leydig cells. We therefore
measured whether AR silencing affected the production of this
hormone, and found no significant differences between untreated
mice (0.8860.69 ng/ml), and mice treated for 3 weeks with cont-
siRNA (0.5360.31 ng/ml) or panAR-siRNA (0.8160.52 ng/ml).
It is thus unlikely that the antitumoral effects of the panAR-siRNA
result from an indirect effect on peripheral tissues. Furthermore, the
AR expression inprostate and testes was not affected by treatment of
micewith the siRNAselective forthe human ARmRNA(Figure 2A)
whereas this siRNA efficiently silenced AR in the human tumor cells
and inhibited their growth in vivo (Figure 1E). In addition, the effects
of hAR- and panAR-siRNAs to inhibit the growth of C4-2 tumors
were very similar (see below, Figure 3C). Together, these results
demonstrate that the main driver of the antitumoral effects of the
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Figure 2. Silencing of AR in prostate and testes. A: Upper panels,
immunodetection of AR expression in the ventral prostate of mice
treated for 3 weeks with hAR-, cont-, or panAR-siRNA as indicated.
Lower panels, AR expression in testes from mice sacrificed at the end of
the experiments shown in figure 1C, after 2 weeks of treatment (cont-
and panAR-siRNA) or treated for 3 weeks with hAR-siRNA. B: AR and
GST expression in testes from mice treated for 3 weeks with cont-
(black bars) or panAR-siRNA (pAR, white bars). AR and GST levels were
quantified by immunoblot, normalized with actin level, (arbitrary units,
mean6SE, n=10). C: Quantification of apoptotic germ cells (insert) in
testes collected from mice treated for 2 or 3 weeks (mean number/ 100
seminiferous tubules6SE) with cont- (c) or panAR-siRNA (pAR).
**p,0.01 as compared to cont-siRNA treated group.
doi:10.1371/journal.pone.0001006.g002
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Treatment of tumors expressing a mutated AR isoform with siRNAs
targeting specifically this mutation would silence AR in the tumor,
while preserving its expression is normal tissues, thus reducing the
unwanted side effects.
AR-siRNA directed inhibition of CRCaP growth
The growth of androgen-dependent tumors, such as LNCaP or
CWR22, xenografted in mice, is efficiently inhibited by castration.
However, tumors eventually adapt to the low androgen environ-
ment and recur. The C4-2 [29] and 22RV1 [30] cell lines were
respectively isolated from LNCaP or CWR22 recurring tumors
and develop in females and in males castrated or treated with
bicalutamide [14,31]. Although C4-2 cells divide in androgen-
depleted medium, androgens still efficiently induced the transcrip-
tion of a 4xARE-luciferase reporter construct (Figure S4A and
S4B), confirming that AR is still functional in these cells. However,
bicalutamide failed to antagonize the androgen-induced transcrip-
tion (Figure S4B). In contrast, AR silencing in C4-2 cells, abolished
the induction of transcription by androgens (Figure S4B). We then
transfected AR-siRNA into C4-2 and 22RV1 cells and compared
the kinetics of the AR protein level, the cells’ proliferation,
quantified by the MTT activity, and apoptosis, measured with
a caspases assay were affected. In C4-2 cells, the AR protein level
was markedly reduced 2 days after transfection (Figure 3A, grey
box plots). Cells’ proliferation diminished starting from day 3
(Figure 3A, black bars) and apoptosis increased significantly in C4-
2 cells on day 4 and 5 (Figure 3A, white bars). In 22RV1 cells, the
AR-siRNA effect appeared less pronounced: the AR protein level
was unaffected until day 3 and the proliferation was reduced only
after day 4. Moreover, AR silencing did not induce any significant
increase in caspases-dependent apoptosis during the 5 first days
following transfection (Figure 3A). Therefore, 5 days after trans-
fection, the number of viable cells was higher in 22RV1 than in
C4-2 cells.
The Vascular Endothelial Growth Factor (VEGF), which is
a key regulator of angiogenesis in the prostate, is upregulated by
androgens in the normal prostate and in androgen-dependent
cells, through indirect transcriptional [32,33] or post-transcrip-
tional [34] mechanisms. Although CRCaP tumors are highly
angiogenic [35], the role of AR in the control of VEGF production
in these tumors was not studied so far. Importantly, we observed
that AR silencing reduced the VEGF synthesis in LNCaP as well
as in C4-2 and 22RV1 cells (Figure 3B), demonstrating that VEGF
is still regulated by AR in advanced prostate cancers.
Our in vivo studies using the LNCaP model demonstrated the
efficiency and specificity of the antitumoral effects produced by
AR silencing. We then studied the effects of the two different AR-
siRNAs on the in vivo growth of castration-resistant tumors. We
first grafted C4-2 cells to nude mice and, after a month, once
vascularized tumors were exponentially growing, and reached
a mean tumor volume of 129.9629.1 mm
3, mice were random-
ized to receive cont-, or panAR-, or hAR-siRNA. In contrast with
castration or bicalutamide, which do not affect the development of
C4-2 tumors [36], both the panAR- and the hAR-siRNA
efficiently inhibited the C4-2 tumor growth (Figure 3C). In non-
necrotic regions, mainly at the periphery of the tumor, a strong
reduction in the level of AR expression and in the proportion of
KI67-positive proliferating cells was observed (Figure 3D).
Similarly, treatment of mice bearing 22RV1 tumors (mean
tumor volume on the day of first siRNA administration:
224.66104.0 mm
3) with AR-siRNA markedly repressed the
tumor growth (Figure 3E). Despite the presence of large necrotic
regions in C4-2 and 22RV1 tumors treated with AR-siRNA, we
only seldom observed shrinkage of tumors. This may be due to the
strong fibrotic reaction also observed in these tumors. The external
volume of the tumors therefore is likely not proportional to the
number of viable tumor cells. To further establish that 22RV1
were resistant to castration levels of testosterone and that the AR-
siRNA was not dependent on indirect effects on prostate or testes,
22RV1 cells were grafted into female nude mice. Mice bearing
exponentially growing tumors with a mean volume of 300 mm
3
were treated with hAR-siRNA. This treatment inhibited the tumor
growth efficiently, although the effect was only visible after a week
of treatment (Figure S5).
Importantly, the AR-siRNA treatment of C4-2 and 22RV1
tumors translated into a significant reduction in the number and size
of blood vessels (Figure 3D and 3F). This reduction came along with
an inhibition of the VEGF production by the human tumor cells
(Figure 3G), in agreement with the in vitro data (Figure 3B).
Quantification of siRNA in tumors and mouse tissues
To further demonstrate that the antitumoral effects of AR-siRNA
in CRCaP resulted from the uptake of the injected naked-siRNA
into tumors, we adapted a qRT-PCR method recently set up to
quantify miRNAs [37]. A stem-loop primer, with an 8 bases-long
overhang complementary to the 39 end of the hAR-siRNA
antisense strand, was annealed at 30uC with known amounts of
this antisense strand. Reverse transcription was performed and the
product amplified by qPCR. The assay shows an excellent
transfected cell population, set to 1. Each box plot is composed of 5 horizontal lines displaying the 10th, 25th, 50th, 75th and 90th percentiles. In sister
wells, the MTT activity (black bars) in AR-siRNA treated cells was measured and expressed as a fraction of that of cont-siRNA transfected cells. The
measured caspases activities (white bars) were expressed using the following formula: (caspases/MTT in AR-siRNA treated cells)/(caspases/MTT in
cont-siRNA treated cells). B: Relative VEGF protein content in the medium of LNCaP, C4-2 or 22RV1 cells, 72 h after transfection of cells with control
(dark grey bars) or hAR-siRNA (light grey bars) (mean6SE, n=5 to 7 independent experiments). The medium was not changed after transfection.
**p,0.01 as compared to values in cont-siRNA transfected cells set to 1. C: Mice bearing C4-2 vascularized and exponentially growing tumors were
randomized and received daily i.p. injections of cont-siRNA (Black symbols), hAR-siRNA (white symbols) or panAR-siRNA (grey symbols); tumor volume
(cm
3, mean6SE n=6-12). *p,0.05 and **p,0.01 comparing panAR-siRNA to cont-siRNA treated tumors (stars above the curves) or comparing hAR-
siRNA to cont-siRNA treated tumors (stars below the curves). D: Frozen sections of regions at the periphery of tumors from C were immunostained by
indirect immunofluorescence with AR, KI67 or Collagen-IV antibodies and observed by epifluorescence. Photographs were taken with a 63x (AR, KI67)
or 10x (Coll-IV) objective, using the same exposure parameters for cont- and AR-siRNA treated tumors. A representative tumor from each group is
shown. E: Male mice bearing exponentially growing 22RV1 tumors were randomized and received either cont- (Black symbols) or hAR-siRNA (white
symbols); tumor volume (cm
3, mean6SE, n=5). *p,0.05 and **p,0.01 comparing panAR-siRNA to cont-siRNA treated tumors. F: Mean microvessels
density (number of vessels/arbitrary surface unit) in at least 10 non overlapping high-power fields from tumors treated with cont- (black bars) or AR-
siRNA (gray bars) in C4-2 or 22RV1 tumors. Necrotic regions were not included in the study. **p,0.01 as compared to cont-siRNA treated group. G:
human VEGF quantification in tumor homogenates from C4-2 or 22RV1 tumors in mice treated with cont-siRNA (black bars) or AR-siRNA (gray bars)
(ng/mg of protein, mean6SEM). *p,0.05 as compared to cont-siRNA treated group.
doi:10.1371/journal.pone.0001006.g003
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cycle threshold (CT) value, with a dynamic range of at least 7 logs.
This method is sensitive enough to detect 10,000 siRNA molecules
(Figure 4A). Total RNA extracted from mouse tissues and 22RV1
tumors was then reverse transcribed and amplified, and the
number of siRNA molecules was determined by comparison with
the standard curve. No signal was amplified in RNA extracted
from liver, testes or tumors of mice treated with cont-siRNA
(Figure 4B). In contrast, the antisense strand was amplified in
tumors, liver, testis and prostate dissected from mice injected with
3 mg of hAR-siRNA (Figure 4B), demonstrating the uptake of
naked siRNA injected i.p. This sensitive assay will allow studying
further the pharmacokinetics and biodisponibility of siRNA
injected in mice (Gilbert et al, in preparation).
DISCUSSION
Specific gene silencing, and RNA interference in particular, offers
new exciting therapeutic perspectives for a number of pathologies,
including cancers. In this perspective, RNAi-directed silencing in
vivo must achieve efficiency, safety and specificity. Infection of cells
with lentiviral vectors expressing short hairpin RNA (shRNA),
triggers a strong silencing of the target, but therapeutic applica-
tions of this approach are limited by risks linked to the stable
integration of the viral genome in the host, by the difficulty to
infect in vivo a large number of cells and by toxic effects resulting
from the saturation of the miRNA maturation machinery [38]. We
thus chose to use synthetic siRNAs. Mice were treated by daily i.p.
injections of small amounts of unmodified siRNAs (125 mg/kg)
diluted in saline. We did not observe any change in the weight,
behavior and aspect of organs at dissection of mice treated for
3 weeks. As compared to other studies, reviewed in [39], where up
to 50 mg/kg of stabilized and/or vectorized siRNAs were used,
our settings strongly limit possible toxic or immune effects reported
with some chemical modifications of siRNA or vectorization
agents [40]. Low siRNA dosing also keeps to a minimum the
always possible dose-dependent off-target effects [41].
Several groups injected under a normal pressure small amounts
of naked siRNAs into mice and reported the efficient silencing of
genes such as VEGF [20], CEACAM6 [42], EphA2 [43], or Bcl2
[44]. Biodistribution studies using radiolabeled naked siRNAs
[44,45] showed that siRNAs rapidly exit the blood compartment
and enter into various tissues. However, this technique does not
demonstrate the integrity of siRNAs into tissues. We demonstrate,
and quantify here for the first time, the uptake of siRNAs into
tumors and mouse tissues. The blood vessels density in tumors
from AR-siRNA treated mice was low (Figure 3C) and,
accordingly, the number of siRNA copies detected in these tumors
was of the same order of magnitude than that measured in testes,
which are poorly vascularized, whereas the siRNA uptake
appeared more efficient in liver and prostate. However the
number of siRNA molecules within tumor cells is likely under-
estimated, due to the heterogeneity of necrotic and fibrotic tumors,
the difficulty to quantify the number of viable cells within a tumor,
and the presence of nucleases released by dying cells during the
RNA purification process. It is still unclear today which trans-
porter, among the several membrane proteins identified [46], is
really involved in the uptake of naked oligodeoxynucleotides
(ODNs) demonstrated in some clinical trials [47]. Similarly, an
homologue of the dsRNA transporter of C. elegans, Sid-1, was
recently shown to transport siRNAs into mammalian cells [48].
However, we could not correlate the sid-1 mRNA level with the
uptake of siRNA into mouse tissues (data not shown), and it is thus
likely that other transporters are also involved. Despite the fact
that the molecular mechanism of siRNA uptake into mammalian
cells in vivo is still under investigation, it is of note that ongoing
clinical trials of siRNAs are performed with naked molecules [49].
The role of AR in androgen-dependent prostate carcinomas has
been well established over years, and recently confirmed using an
inducible AR-shRNA lentiviral construct in LNCaP tumors [50].
We therefore used this cellular model to set up the technical
conditions to silence AR in exponentially growing tumors using
synthetic AR-siRNA. The uptake of panAR-siRNA triggered
a strong silencing of AR in tumor cells, prostate and testes which
did not modify the blood level of testosterone. Interestingly, the
sequence specificity of siRNA allowed here discriminating in vivo
the closely related mouse and human AR mRNAs: treatment with
hAR-siRNA silenced AR in tumor cells and inhibited the tumor
growth while preserving AR expression in mouse prostate and testes.
Treating tumors with hAR-siRNA was as efficient as treating with
the antagonist bicalutamide, which affects AR signaling in prostate
and testes. The inhibition of the growth of C4-2 tumors by panAR-
or hAR-siRNAs in intact males was comparable. All together, these
data demonstrate that the inhibition of AR signaling outside the
tumor does not participate in the antitumoral effect, opening
promisingperspectivesfordeveloping tumor-specifictreatmentswith
reduced side effects for patients.
Prostate tumor cells can escape androgen-ablation therapies by
multiple mechanisms involving the androgen receptor. The
functionality of AR in these resistant cells is well established, but
this does not foretell if AR silencing is sufficient to inhibit
proliferation and trigger apoptosis, as other molecular events
accumulating along tumor progression could help cells bypassing
AR signaling. Of note, DU145 and PC3 cell lines, which no longer
express AR, are representative of a proportion of advanced
prostate tumors where AR is no longer required for tumor growth
[11]. Several studies evaluated the role of AR in CRCaP cells in
vitro, leading to contradictory conclusions: Gosh et al., showed that
the main driver of CRCaP cells’ division was p70S6 kinase, and
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Figure 4. Quantification of siRNA copies in CRCaP tumors and mouse
tissues. A: Dynamic range and sensitivity of the hAR-siRNA antisense
strand assay. 10
4 to 10
11 copies of the antisense strand of hAR-siRNA
were reverse-transcribed using a stem-loop primer. The product was
amplified in the presence of SyberGreen and the cycle threshold (CT)
plotted against the log of the number of copies of the input target. B:
Detection of the antisense strand of hAR-siRNA in tumors (tum), testis
(test), prostate (prost) and liver of mice treated with 3 mg of cont- (c) or
hAR-siRNA (AR) injected i.p. in 50 ml of saline. The number of siRNA
copies is normalized to the tissue weight (mean6SE n=3).
doi:10.1371/journal.pone.0001006.g004
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silencing in these cells produced only a limited [15] or a non
statistically significant effect [16]. In contrast, Zegarra-Moro et al.
[13] showed that the microinjection of AR antibodies almost
completely arrested C4-2 cells’ proliferation, whereas Liao et al.
[17] reported that AR silencing induced their massive apoptosis.
In our hands, AR silencing produced a time-dependent inhibition
of cells’ proliferation in C4-2 as in 22RV1 cells, but triggered
apoptosis in C4-2 cells only, at least during the time-course of this
experiment. Using a lentiviral AR-shRNA expressing vector, Chen
et al [6] stably silenced AR in LAPC4 and in castration-resistant
LNCaP cells, which then failed to develop tumors once grafted
into SCID mice. However, as the authors did not report if the
cells’ proliferation was affected or not before the grafting, the in vivo
data are difficult to interpret. From all the above studies, it was
therefore not possible to foretell whether AR was a key target in
established resistant tumors.
We used to address this question one ADCaP and two unrelated
CRCaP models and checked during at least 5 days that each
tumor was exponentially growing before randomization for siRNA
treatment. AR-siRNA induced in all three tumor models a strong
inhibitory effect. The tumors that were smaller at the start of the
treatment (for example 50 mm
3 in a 24 g-weighing mouse in
Figure 1C, which would correspond to a tumor of 146 g in a 70
kg-weighing man) responded better than the larger ones.
It is well established that AR regulates the VEGF production in
the normal prostate as in androgen-dependent tumors. The VEGF
level is very tightly controlled, at the transcriptional and post
transcriptional levels, and AR is likely involved in several of these
mechanisms [32,33,34]. Tumors that became resistant to
hormonal manipulations are very angiogenic [35] and express
high VEGF levels. Importantly, we demonstrate here for the first
time that, in vitro as in vivo, AR still controls the VEGF production
in CRCaP. AR silencing in vivo reduces VEGF synthesis, triggering
a reduction in the blood vessels density, although other modulators
of angiogenesis regulated by androgens [35,51,52] could also
participate in this process. Therefore, part of the antitumoral
effects produced by AR-siRNA likely result from the inhibition of
angiogenesis in the treated tumors. Our results demonstrate that
androgen dependent, but also and more importantly, exponen-
tially growing and vascularized castration-resistant prostate
tumors, are still dependent on the expression of a functional AR
for their growth and angiogenesis.
Importantly, siRNA-directed silencing of AR allows inhibiting
the synthesis of overexpressed wild type receptors, as well as
mutated or stabilized isoforms that can be encountered in
advanced prostate carcinomas. The strong antitumoral effects
triggered by siRNA-directed silencing of AR, which results from
a combination of antiproliferative and antiangiogenic effects,
opens exciting therapeutic perspectives for treating advanced
prostate tumors that became resistant to hormonal manipulations,
for which treatments available today are only palliative.
MATERIALS AND METHODS
Cell culture and in vitro assays
LNCaP, 22RV1 and C4-2 cells were grown in RMPI containing
10% of fetal calf serum. In vitro transfections of plasmids and
siRNA (10 nM) were performed by a standard calcium phosphate
precipitation method or, in Figure 3A, using the HiPerfect reagent
(Qiagen, Courtaboeuf, France). Androgen reporter assays were
performed as previously described [35]. When stated, cells were
incubated in medium containing 10% charcoal-stripped fetal calf
serum and then treated with R1881, a synthetic AR-specific
agonist (0.1–0.5 nM, NEN, Zaventem, Belgium), or with the AR-
antagonist bicalutamide (100 nM, generous gift of AstraZeneca) or
with vehicle. Cell proliferation and viability were quantified either
by counting cells excluding the trypan blue or using the MTT
assay (WST-1, Roche). Caspases activities were measured using
a fluorimetric quantification assay (Apo-One caspase 3/7 assay,
Promega, Lyon France).
siRNA
Synthetic siRNA were purchased from Dharmacon (option A4,
Boulder, Co). Sequences are indicated in table S1.
Animals, siRNA injection and tumorigenicity assays
Studies involving animals, including housing and care, method of
euthanasia and experimental protocols were conducted in
accordance with the local animal ethical committee in the Institut
Andre ´ Lwoff in Villejuif, France. Tumor cells (2610
6 cells/mouse)
were injected subcutaneously in 50% (v:v) matrigel (BD
biosciences) to 6–8 weeks old male nude mice and measured as
previously described [35]. The tumor take was about 65% for
LNCaP cells, and 80% for C4-2 and .90% , in males as in
females, for 22RV1 cells. When indicated, 50 ml of a 4.2 mM
solution of siRNA diluted in PBS were injected i.p. on a daily
basis. Bicalutamide (50 mg/kg/day, Casodex, AstraZeneca) was
administered orally.
Real-time RT-PCR siRNA and mRNA analysis
Total RNA was isolated using TRIzol reagent (Invitrogen, Cergy
Pontoise, France). Relative gene expression was analyzed using
QuantiTect SYBR Green RT-PCR kit (QIAGEN, Courtaboeuf,
France). Human Cyclophilin A was used as an internal control.
For siRNA detection, 500 ng of total RNA was annealed at 30uC
for 30 min with a stem-loop primer and then reverse transcribed
(Taqman microRNA reverse transcriptase kit, Applied). The RT
product was then amplified, using the same kit as above.
Sequences of primers are indicated in table S2. Threshold cycle
(CT) values, defined as the fractional cycle number at which the
fluorescence passes the fixed threshold, were converted into
absolute copy numbers using a standard curve from synthetic
hAR-siRNA antisense strand.
Immunodetection and apoptosis detection
Protein detection by immunoblotting was performed using
antibodies raised against AR (rabbit polyclonal antibody sc-816
Santa Cruz, CA), Gluthation-S Transferase alpha 4 (NCL-
GSTalpha, Novocastra-Tebu, Le Perray en Yvelines, France),
actin (clone AA 20–33, Sigma, Meylan, France) or tubulin (mouse
monoclonal DM1A, Sigma). Vascular Endothelial Growth Factor
(VEGF) was quantified using an ELISA kit specific for human
VEGF (R&D Systems, Minneapolis, MN, USA). Testosterone in
blood samples was quantified by RIA (Beckman-Coulter, Ville-
pinte, France). Immunodetection on paraffin embedded tissues or
cryostat sections was performed using antibodies raised against AR
(rabbit polyclonal: Santacruz sc-816 or mouse monoclonal:
Neomarkers Ab1), KI67 (Neomarkers, rabbit monoclonal) to label
proliferative cells or Collagen IV (Novotec, Lyon, France) to detect
microvessels. TUNEL labeling was performed as previously
described [53].
Statistical analysis
Using a t-test, results were considered statistically different when
calculated p values were ,0.05 (*) or ,0.01 (**).
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Figure S1 Control of the exponential growth of tumors before
first treatment. Before randomization of mice for siRNA
treatment, the exponential growth of tumors was verified by
plotting the neperian logarithm of the tumor volume as a function
of time. This analysis was performed for each individual tumor
studied. The figure represents the ln(tumor volume), mean6SEM,
of tumors studied in figure 1C, before the first siRNA treatment.
Found at: doi:10.1371/journal.pone.0001006.s001 (0.53 MB TIF)
Figure S2 Effect of panARsiRNA treatment on the growth of an
AR-negative tumor . JT8 fibrosarcoma cells, which do not express
AR, were grafted to male nude mice. Starting from day 8, mice
received daily i.p. injections of 3 mg of cont-siRNA (black symbols)
or panAR-siRNA (white symbols). The tumor volume (mean6SE,
n=6) was not different between the two groups. VEGF-siRNA
injected with the same protocol were shown previously to induce
70% reduction in VEGF production and a marked growth
inhibition of these tumors (Filleur et al., cancer res. 2003).
Found at: doi:10.1371/journal.pone.0001006.s002 (0.61 MB EPS)
Figure S3 Naked siRNAs do not induce in mice a typeI-
Interferon response. Interferon-a was quantified by ELISA (R&D)
in serum collected from mice bearing LNCaP tumors and treated
daily for 15–21 days with 3 mg of either cont-siRNA, hAR-siRNA
or panAR-siRNA (experiments shown in Fig 2a and 3a). Similar
results were obtained when mice were treated with siRNA for only
3 days (not shown). As controls, naive mice were injected i.p. for 2
consecutive days with 80 mgo r3mg of poly[I ]-poly[C], or with
80 mg of poly[I ]-poly[C] pretreated with RNAse A. Results are
expressed in pg/ml of serum on a logaritmic scale.
Found at: doi:10.1371/journal.pone.0001006.s003 (0.61 MB EPS)
Figure S4 Effects of bicalutamide and siRNA on LNCaP and
C4-2 cells in vitro. A: LNcaP (grey bars) or C4-2 (black bars) cells
were incubated for 3 days in medium containing 10% of charcoal-
filtered serum supplemented with R1881 (0.5 nM) or bicalutamide
(10-5M) as indicated. The cell number was compared to that of
untreated cells. B: A 4xARE-luciferase reporter gene was co-
transfected into LNCaP (grey bars) or C4-2 cells (black bars) along
with cont- or hAR-siRNA. Cells were then incubated in medium
containing 10% of charcoal-filtered serum supplemented with
R1881 (0.5 nM) or bicalutamide (10-5M) as indicated. The
luciferase activity was quantified 48 h after transfection.
Found at: doi:10.1371/journal.pone.0001006.s004 (0.72 MB EPS)
Figure S5 Inhibition of the 22RV1 tumor growth in female mice
by hAR-siRNA treatment. 6 weeks-old female swiss nu/nu mice
were grafted with one million 22RV1 cells. Once tumors grew
exponentially, mice were randomized (6 mice per group) and
received daily i.p. injections of 3 mg of cont-siRNA or hAR-siRNA
diluted in PBS.
Found at: doi:10.1371/journal.pone.0001006.s005 (0.50 MB EPS)
Table S1
Found at: doi:10.1371/journal.pone.0001006.s006 (0.03 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0001006.s007 (0.03 MB
DOC)
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